Targeting gene delivery to prostatic cancer with mAb-conjugated polyamidoamine dendrimers / 中国药学杂志
Chinese Pharmaceutical Journal
; (24): 418-422, 2012.
Article
in Zh
| WPRIM
| ID: wpr-860784
Responsible library:
WPRO
ABSTRACT
OBJECTIVE: Aim to construct a novel polymer gene delivery system based on a new kind of dendrimer-polyamidoamine (PAMAM). With the modification of polyethylene glycol (PEG) and YPSMA-1 monoclonal antibody (mAb), PAMAM-PEG-mAb was successfully synthesized as a novel gene vector targeting to the prostatic cancer. METHODS: NMR was used to characterize PAMAM-PEG-mAb. The cellular uptake and prostatic cancer (PCa) distribution experiments were employed to explore its biological characteristics and PCa cell (PC3 and LNCaP) targeting ability. RESULTS: NMR results demonstrated the successful synthesis of PAMAM-PEG-mAb. The cellular uptake of vectors was concentration-dependent. The gene expression in vitro indicated that the modification of mAb could increase the gene expression efficiency and PCa targeting ability of PAMAM vectors to LNCaP ( PSMA overexpressing prostate cancer cells). CONCLUSION: PAMAM-PEG-mAb is a potential gene delivery vector targeting to PCa. Copyright 2012 by the Chinese Pharmaceutical Association.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Chinese Pharmaceutical Journal
Year:
2012
Type:
Article